By Content Writer / 16th June 2026
As per recent global data, lung cancer is one of the major cause of cancer death worldwide with 2.2 million new cases and around 1.8 million deaths. Most of the cases are non-small cell lung cancer (NSCLC), a common type of lung cancer. It is a slow growing but fatal from of cancer if diagnosed lately. However, molecular testing has brought changes in NSCLC treatment from chemotherapy to precision targeted therapy. Targeted therapy treat NSCLC by blocking specific pathways that promotes growth of cancer cells. Let’s understand about non-small cell lung cancer from causes to cutting-edge targeted therapies.
NSCLC is a most common type of lung cancer types that behave more slowly than small cell lung cancer. It is responsible for around 80–85% of lung cancers. It originates from epithelial cells of the lung.
Types (histologic):
Common symptoms:
Diagnosis pathway:
Lumakras 120 mg Tablet is a targeted therapy medicine with sotorasib as an active ingredient. It is a KRAS G12C inhibitor that works by blocking the action of KRAS G12C protein. By blocking specific protein pathway it slows down the tumor growth and progression of cancer.
Doctor commonly prescribe this tablet to adults with KRAS G12C-mutated locally advanced or metastatic NSCLC. It is an approved as well as potent targeted medicine especially for a previously difficult-to-target mutation.
Sotoxen 120 mg Capsule is a targeted therapy anticancer medicine with sotorasib as an active ingredient. It is prescribed to treat KRAS G12C tumours and also as a prior therapy in advanced NSCLC.
It is a KRAS G12C inhibitor which control the can spread by inhibiting the action of KRAS G12C protein. It can be used as a part of combination therapy to increase the effectiveness of the treatment. It is an effective medicine to treat NSCLC especially in advanced stages.
Exkivity 40 mg Capsule is a prescription based anticancer medicine. It contains mobocertinib as an active ingredient that belongs to the class of drug known as tyrosine kinase inhibitor. It works by targeting EGFR exon 20 insertion mutations and inhibit its pathway to control the cancer progression. Doctor commonly prescribes Exkivity 40 mg to treat non-small cell lung cancer in the patient with exon 20 insertion mutations. It is a potent treatment option in advance stage NSCLC.
Moboxen 40 mg Capsule is a prescription based targeted therapy anticancer medicine. It contains mobocertinib as an active ingredient that belongs to the drug class of EGFR inhibitors. Doctor prescribes Moboxen 40 mg to treat non-small cell lung cancer in patient with specific EGFR exon 20 insertion-positive gene mutation. It works by inhibiting the action of specific protein to control the cancer cell multiplication and progression. It should be taken under strict medical supervision like any other medicine.
Alecensa 150 mg Capsule is an anticancer medicine with alectinib as an active ingredient. This medicine belongs to the class of drugs known as ALK (anaplastic lymphoma kinase) inhibitor. It is prescribed to treat patients with ALK-positive metastatic non-small cell lung cancer. It significantly improves the survival rate and treatment outcome, especially in advance stages. It is used as a first line of treatment option in ALK-positive NSCLC due to its effectiveness.
Alecnib 150 mg Capsule is an anticancer medicine that contains alectinib as an active ingredient. It is a RET tyrosine kinase inhibitor and ALK inhibitor. It is prescribed to the adult patients with ALK-positive non-small cell lung cancer. It is a monotherapy medicine used as a first line of treatment for advanced stages NSCLC. It works by blocking the action of specific protein to stop the growth of cancer cells. It is a potent medicine to treat ALK-positive NSCLC.
In Conclusion, Targeted therapy has reshaped the treatment strategy of non-small cell lung cancer. In today’s time, molecular testing determines treatment pathways, and precision drugs. Modern treatment options usually provide better tolerability with significant improvement in survival rate. However, lifestyle changes, awareness, early diagnosis, and right treatment approach can improve the outcome.
Some of the most potent targeted drugs including Alecnib 150mg Capsule, Alecensa 150mg Capsule, Moboxen 40mg Capsule, Exkivity 40mg Capsule, Sotoxen 120mg Capsule, and Lumakras 120mg Tablet available at Globans Pharma. It offers genuine life saving drugs worldwide at an affordable price range with fast door step delivery.
Q –What side effects are common during the treatment with targeted medicines?
However, the side effects vary by patient and type of drug. Although the side effects with targeted medicines are fewer and manageable. Regular monitoring is recommended during the treatment.
Q –Do all NSCLC patients get targeted therapy?
No targeted therapy is used when molecular testing shows an actionable mutation including EGFR, ALK, KRAS, or ROS1. Patients without those mutations may receive immunotherapy, chemotherapy, or combinations instead.
Q –Are these targeted drugs safe for the brain metastases
Some, like alectinib (ALK inhibitor), have good CNS penetration and are effective against brain metastases. However, not all targeted agents share this property.
Q –How is a KRAS G12C, EGFR exon 20, or ALK fusion detected
Through molecular testing of tumour tissue (NGS panels) or plasma (liquid biopsy). Testing should be done at diagnosis of advanced disease.